We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Actelion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for OPSUMIT® (macitentan) in the treatment of ....
The FDA granted Bayer and Merck & Co. a breakthrough device designation for an artificial intelligence-based pattern recognition software used to spot a rare form of pulmonary hypertension in CT scans......
Bayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial intelligence software they are jointly developing.
NHS England is funding a pioneering procedure that will improve treatment outcomes for patients with a lung disease called Chronic Thromboembolic Pulmonary Hypertension (CTEPH).